Avivagen Animal Health Begins Marketing In Canada

Avivagen Animal Health Inc., a new subsidiary of Chemaphor Inc., has officially begun commercial operations.

Chemaphor Inc. of Ottawa, Ontario, reported today that its new subsidiary, Avivagen Animal Health Inc., has begun commercial operations.

Avivagen is now marketing exclusively through the veterinary channel in Canada its Oximunol Chewable Tablets for dogs and its in-licensed VetStem RC regenerative cell treatment for dogs, horses and cats.

A dedicated interactive website has also been launched.

“We believe it is important to take full advantage of the social media capabilities of online communities, to communicate with and build the all-important, long-term relationships with pet parents and veterinarians,” said Dave Hankinson, CEO of Chemaphor and Avivagen. “At the same time this discussion creates awareness of and buying interest in our novel and innovative products and services.

“According, we have appointed a dedicated consumer and marketing communications coordinator, Jennifer Febel, who will be blogging on the website and facilitating discussion with website visitors through services such as Facebook and Twitter, as well as by regular e-mail.”

Hankinson invited veterinarians who would like to discuss aspects of the company’s products and services to contact Dr. Isabelle Epshtein-Verzberger, veterinary research scientist, at 902-940-7395 or i.verzberger@avivagen.com.


Leave a Comment


Your email address will not be published. Required fields are marked *



Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.